CENTESSA PHARMACEUTICALS PLC's ticker is CNTA and the CUSIP is 152309100. A total of 41 filers reported holding CENTESSA PHARMACEUTICALS PLC in Q3 2021. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $5,490,000 | -45.7% | 1,127,273 | 0.0% | 0.03% | -46.6% |
| Q1 2022 | $10,112,000 | -20.3% | 1,127,273 | 0.0% | 0.06% | -6.5% |
| Q4 2021 | $12,693,000 | -32.6% | 1,127,273 | 0.0% | 0.06% | -25.3% |
| Q3 2021 | $18,825,000 | +111.9% | 1,127,273 | +181.8% | 0.08% | +112.8% |
| Q2 2021 | $8,884,000 | – | 400,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Index Venture Life Associates VI Ltd | 9,961,789 | $89,357,000 | 100.00% |
| Medicxi Ventures Management (Jersey) Ltd | 19,963,157 | $179,070,000 | 48.51% |
| Vida Ventures Advisors, LLC | 3,931,818 | $35,268,000 | 20.51% |
| OUP Management Co., LLC | 2,937,615 | $26,350,000 | 20.06% |
| Samsara BioCapital, LLC | 1,884,096 | $16,900,000 | 4.26% |
| Kynam Capital Management, LP | 669,100 | $6,002,000 | 1.95% |
| Cormorant Asset Management, LP | 2,489,894 | $22,334,000 | 1.72% |
| GENERAL ATLANTIC, L.P. | 9,681,818 | $86,846,000 | 0.79% |
| RA Capital Management | 3,577,094 | $32,087,000 | 0.70% |
| BVF INC/IL | 1,755,545 | $15,747,000 | 0.63% |